It interacts directly with the DOC-2/DAB2 (also known as differentially expressed in ovarian carcinoma-2, DOC-2) protein that appears to be a tumour suppressor in malignant tumours, including mammary, prostate and ovarian cancers (Fulop et al, 1998; Zhou and Hsieh, 2001). Here, DAB2 is linked to neoplasm.